Endocrine Abstracts

Breakpoint cluster region abelson fusion oncoprotein (BCR-ABL) targeted tyrosine kinase inhibitors (TKIs) are widely used in long-term medications of hematological malignancies. Numerous clinical observations confirmed that these drugs significantly modify the physiology of bone tissue as a side effect. Currently, there are numerous contradictory results regarding the complex effects of TKIs on bone metabolism, as well as there is no clear evidence to explain them, either in t...